Notable Labs ( NASDAQ: NTBL ) on Wednesday announced progress for the Phase 2 volasertib program, following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib in the coming months. Based on its plan, the company expects to have initial data from the dose optimization lead-in during Q4 2024, initiate selective enrollment of PMP-predicted responders after that, and start to report initial efficacy results during H1 2025.
Press release. More on Notable Labs Historical earnings data for Notable Labs Financial information for Notable Labs.
